Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 253

1.

Genetic Polymorphisms Implicated in Nonalcoholic Liver Disease or Selected Other Disorders Have No Influence on Drug-Induced Liver Injury.

Bonkovsky HL, Severson T, Nicoletti P, Barnhart H, Serrano J, Chalasani N, Fontana RJ, Watkins PB, Navarro V, Stolz A, Daly AK, Aithal GP, Odin J; US DILIN Investigators.

Hepatol Commun. 2019 Jun 6;3(8):1032-1035. doi: 10.1002/hep4.1382. eCollection 2019 Aug.

2.

Endocytosis and Lack of Cytotoxicity of Alkyl-Capped Silicon Quantum Dots Prepared from Porous Silicon.

Phatvej W, Datta HK, Wilkinson SC, Mutch E, Daly AK, Horrocks BR.

Materials (Basel). 2019 May 25;12(10). pii: E1702. doi: 10.3390/ma12101702.

3.

Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions.

Nicoletti P, Barrett S, McEvoy L, Daly AK, Aithal G, Lucena MI, Andrade RJ, Wadelius M, Hallberg P, Stephens C, Bjornsson ES, Friedmann P, Kainu K, Laitinen T, Marson A, Molokhia M, Phillips E, Pichler W, Romano A, Shear N, Sills G, Tanno LK, Swale A, Floratos A, Shen Y, Nelson MR, Watkins PB, Daly MJ, Morris AP, Alfirevic A, Pirmohamed M.

Clin Pharmacol Ther. 2019 May 7. doi: 10.1002/cpt.1493. [Epub ahead of print]

PMID:
31066027
4.

Next-Generation Sequencing of PTGS Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury.

Lucena MI, García-Martín E, Daly AK, Blanca M, Andrade RJ, Agúndez JAG.

Front Genet. 2019 Feb 28;10:134. doi: 10.3389/fgene.2019.00134. eCollection 2019.

5.

A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury.

Cirulli ET, Nicoletti P, Abramson K, Andrade RJ, Bjornsson ES, Chalasani N, Fontana RJ, Hallberg P, Li YJ, Lucena MI, Long N, Molokhia M, Nelson MR, Odin JA, Pirmohamed M, Rafnar T, Serrano J, Stefánsson K, Stolz A, Daly AK, Aithal GP, Watkins PB; Drug-Induced Liver Injury Network (DILIN) investigators; International DILI consortium (iDILIC).

Gastroenterology. 2019 May;156(6):1707-1716.e2. doi: 10.1053/j.gastro.2019.01.034. Epub 2019 Jan 18.

PMID:
30664875
6.

Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles.

Nicoletti P, Aithal GP, Chamberlain TC, Coulthard S, Alshabeeb M, Grove JI, Andrade RJ, Bjornsson E, Dillon JF, Hallberg P, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Wadelius M, Shen Y, Nelson MR, Daly AK; International Drug-Induced Liver Injury Consortium (iDILIC).

Clin Pharmacol Ther. 2019 Jul;106(1):245-253. doi: 10.1002/cpt.1375. Epub 2019 Mar 19.

PMID:
30661239
7.

HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors.

Usui T, Tailor A, Faulkner L, Meng X, Farrell J, Daly AK, Dear GJ, Park BK, Naisbitt DJ.

Chem Res Toxicol. 2018 Oct 15;31(10):1022-1024. doi: 10.1021/acs.chemrestox.8b00163. Epub 2018 Sep 13.

PMID:
30179004
8.

Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: a perspective.

Athersuch TJ, Antoine DJ, Boobis AR, Coen M, Daly AK, Possamai L, Nicholson JK, Wilson ID.

Toxicol Res (Camb). 2018 Mar 6;7(3):347-357. doi: 10.1039/c7tx00340d. eCollection 2018 May 8. Review.

9.

Pharmacogenetics of Adverse Drug Reactions.

Osanlou O, Pirmohamed M, Daly AK.

Adv Pharmacol. 2018;83:155-190. doi: 10.1016/bs.apha.2018.03.002. Review.

PMID:
29801574
10.

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.

Daly AK, Rettie AE, Fowler DM, Miners JO.

J Pers Med. 2017 Dec 28;8(1). pii: E1. doi: 10.3390/jpm8010001. Review.

11.

Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis.

Whitfield JB, Masson S, Liangpunsakul S, Hyman J, Mueller S, Aithal G, Eyer F, Gleeson D, Thompson A, Stickel F, Soyka M, Daly AK, Cordell HJ, Liang T, Foroud T, Lumeng L, Pirmohamed M, Nalpas B, Bence C, Jacquet JM, Louvet A, Moirand R, Nahon P, Naveau S, Perney P, Podevin P, Haber PS, Seitz HK, Day CP, Mathurin P, Morgan TM, Seth D; GenomALC Consortium.

Alcohol. 2018 Feb;66:1-7. doi: 10.1016/j.alcohol.2017.07.006. Epub 2017 Sep 23.

12.

Pharmacogenetics: a general review on progress to date.

Daly AK.

Br Med Bull. 2017 Dec 1;124(1):65-79. doi: 10.1093/bmb/ldx035. Review.

PMID:
29040422
13.

Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study.

Bakar NS, Neely D, Avery P, Brown C, Daly AK, Kamali F.

Clin Pharmacol Ther. 2018 Jul;104(1):178-187. doi: 10.1002/cpt.887. Epub 2017 Nov 9.

PMID:
28940218
14.

Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor.

Urban TJ, Nicoletti P, Chalasani N, Serrano J, Stolz A, Daly AK, Aithal GP, Dillon J, Navarro V, Odin J, Barnhart H, Ostrov D, Long N, Cirulli ET, Watkins PB, Fontana RJ; Drug-Induced Liver Injury Network (DILIN); Pharmacogenetics of Drug-Induced Liver Injury group (DILIGEN); International Serious Adverse Events Consortium (iSAEC).

J Hepatol. 2017 Jul;67(1):137-144. doi: 10.1016/j.jhep.2017.03.010. Epub 2017 Mar 18.

15.

Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK; International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium.

Gastroenterology. 2017 Apr;152(5):1078-1089. doi: 10.1053/j.gastro.2016.12.016. Epub 2016 Dec 30.

16.

Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury?

Daly AK.

Pharm Res. 2017 Aug;34(8):1564-1569. doi: 10.1007/s11095-016-2091-1. Epub 2016 Dec 27. Review.

17.

Defining drug response for stratified medicine.

Lonergan M, Senn SJ, McNamee C, Daly AK, Sutton R, Hattersley A, Pearson E, Pirmohamed M.

Drug Discov Today. 2017 Jan;22(1):173-179. doi: 10.1016/j.drudis.2016.10.016. Epub 2016 Nov 3. Review.

PMID:
27818254
18.

Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans.

Liu W, Anstee QM, Wang X, Gawrieh S, Gamazon ER, Athinarayanan S, Liu YL, Darlay R, Cordell HJ, Daly AK, Day CP, Chalasani N.

Aging (Albany NY). 2016 Oct 13;9(1):26-40. doi: 10.18632/aging.101067.

19.

The Effect of the CYP1A1*2A Allele on Colorectal Cancer Susceptibility in a British Population.

Öztaş E, Özhan G, Daly AK.

Genet Test Mol Biomarkers. 2016 Aug;20(8):475-7. doi: 10.1089/gtmb.2016.0099. Epub 2016 May 31.

PMID:
27243113
20.

HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury.

Nicoletti P, Werk AN, Sawle A, Shen Y, Urban TJ, Coulthard SA, Bjornsson ES, Cascorbi I, Floratos A, Stammschulte T, Gundert-Remy U, Nelson MR, Aithal GP, Daly AK; International Drug-induced Liver Injury Consortium.

Pharmacogenet Genomics. 2016 May;26(5):218-24. doi: 10.1097/FPC.0000000000000209.

PMID:
26959717
21.

A multi-factorial analysis of response to warfarin in a UK prospective cohort.

Bourgeois S, Jorgensen A, Zhang EJ, Hanson A, Gillman MS, Bumpstead S, Toh CH, Williamson P, Daly AK, Kamali F, Deloukas P, Pirmohamed M.

Genome Med. 2016 Jan 6;8(1):2. doi: 10.1186/s13073-015-0255-y.

22.

Genetics of Alcoholic Liver Disease.

Anstee QM, Daly AK, Day CP.

Semin Liver Dis. 2015 Nov;35(4):361-74. doi: 10.1055/s-0035-1567832. Epub 2015 Dec 16. Review.

PMID:
26676812
23.

Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in Type 2 Diabetes.

Steven S, Hollingsworth KG, Small PK, Woodcock SA, Pucci A, Aribisala B, Al-Mrabeh A, Daly AK, Batterham RL, Taylor R.

Diabetes Care. 2016 Jan;39(1):158-65. doi: 10.2337/dc15-0750. Epub 2015 Dec 1.

PMID:
26628414
24.

Variants in the LGALS9 Gene Are Associated With Development of Liver Disease in Heavy Consumers of Alcohol.

Rosen HR, Golden-Mason L, Daly AK, Yang I, Day CP.

Clin Gastroenterol Hepatol. 2016 May;14(5):762-8.e1. doi: 10.1016/j.cgh.2015.11.005. Epub 2015 Nov 18.

PMID:
26598225
25.

Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.

Kalman LV, Agúndez J, Appell ML, Black JL, Bell GC, Boukouvala S, Bruckner C, Bruford E, Caudle K, Coulthard SA, Daly AK, Del Tredici A, den Dunnen JT, Drozda K, Everts RE, Flockhart D, Freimuth RR, Gaedigk A, Hachad H, Hartshorne T, Ingelman-Sundberg M, Klein TE, Lauschke VM, Maglott DR, McLeod HL, McMillin GA, Meyer UA, Müller DJ, Nickerson DA, Oetting WS, Pacanowski M, Pratt VM, Relling MV, Roberts A, Rubinstein WS, Sangkuhl K, Schwab M, Scott SA, Sim SC, Thirumaran RK, Toji LH, Tyndale RF, van Schaik R, Whirl-Carrillo M, Yeo K, Zanger UM.

Clin Pharmacol Ther. 2016 Feb;99(2):172-85. doi: 10.1002/cpt.280. Epub 2015 Nov 20. Review.

26.

Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.

Daly AK.

Adv Pharmacol. 2015;74:85-111. doi: 10.1016/bs.apha.2015.03.001. Epub 2015 May 11. Review.

PMID:
26233904
27.

Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury.

Kim SH, Saide K, Farrell J, Faulkner L, Tailor A, Ogese M, Daly AK, Pirmohamed M, Park BK, Naisbitt DJ.

Hepatology. 2015 Sep;62(3):887-99. doi: 10.1002/hep.27912. Epub 2015 Jul 23.

PMID:
25998949
28.

Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants.

Marvig CL, Verhoef TI, de Boer A, Kamali F, Redekop K, Pirmohamed M, Daly AK, Manolopoulos VG, Wadelius M, Bouvy M, Maitland-van der Zee AH; EU-PACT consortium.

Thromb Res. 2015 Jul;136(1):69-75. doi: 10.1016/j.thromres.2015.04.026. Epub 2015 Apr 25.

PMID:
25956287
29.

Promiscuous T-cell responses to drugs and drug-haptens.

Yaseen FS, Saide K, Kim SH, Monshi M, Tailor A, Wood S, Meng X, Jenkins R, Faulkner L, Daly AK, Pirmohamed M, Park BK, Naisbitt DJ.

J Allergy Clin Immunol. 2015 Aug;136(2):474-6.e8. doi: 10.1016/j.jaci.2015.02.036. Epub 2015 Apr 22. No abstract available.

PMID:
25910715
30.

Brief report: genetics of alcoholic cirrhosis-GenomALC multinational study.

Whitfield JB, Rahman K, Haber PS, Day CP, Masson S, Daly AK, Cordell HJ, Mueller S, Seitz HK, Liangpunsakul S, Westerhold C, Liang T, Lumeng L, Foroud T, Nalpas B, Mathurin P, Stickel F, Soyka M, Botwin GJ, Morgan TR, Seth D; GenomALC Consortium.

Alcohol Clin Exp Res. 2015 May;39(5):836-42. doi: 10.1111/acer.12693.

31.
32.

Oral anticoagulation: a critique of recent advances and controversies.

Pirmohamed M, Kamali F, Daly AK, Wadelius M.

Trends Pharmacol Sci. 2015 Mar;36(3):153-63. doi: 10.1016/j.tips.2015.01.003. Epub 2015 Feb 17. Review.

PMID:
25698605
33.

TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?

Kahali B, Liu YL, Daly AK, Day CP, Anstee QM, Speliotes EK.

Gastroenterology. 2015 Apr;148(4):679-84. doi: 10.1053/j.gastro.2015.01.038. Epub 2015 Jan 29. No abstract available.

PMID:
25639710
34.

TM6SF2 as a genetic risk factor for fibrosis.

Daly AK, Day CP, Liu YL, Anstee QM.

Hepatology. 2015 Oct;62(4):1321. doi: 10.1002/hep.27656. Epub 2015 Jun 19. No abstract available.

PMID:
25502834
35.

Direct-to-consumer pharmacogenomic testing assessed in a US-based study.

Daly AK.

J R Coll Physicians Edinb. 2014;44(3):212-3. doi: 10.4997/JRCPE.2014.305. No abstract available.

PMID:
25318397
36.

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison ME, Alexander GJ, Piguet AC, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM.

Nat Commun. 2014 Jun 30;5:4309. doi: 10.1038/ncomms5309.

37.

Patients benefit from genetics-guided coumarin anticoagulant therapy.

Maitland-van der Zee AH, Daly AK, Kamali F, Manolopoulous VG, Verhoef TI, Wadelius M, de Boer A, Pirmohamed M; EU-PACT Study Group.

Clin Pharmacol Ther. 2014 Jul;96(1):15-7. doi: 10.1038/clpt.2014.44. Erratum in: Clin Pharmacol Ther. 2014 Sep;96(3):397. Manolopoulos, V G [corrected to Manolopoulous, V G].

PMID:
24942396
38.

N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.

Ng CS, Hasnat A, Al Maruf A, Ahmed MU, Pirmohamed M, Day CP, Aithal GP, Daly AK.

Eur J Clin Pharmacol. 2014 Sep;70(9):1079-86. doi: 10.1007/s00228-014-1703-0. Epub 2014 Jun 3.

PMID:
24888881
39.

Genetic basis of drug-induced liver injury: present and future.

Urban TJ, Daly AK, Aithal GP.

Semin Liver Dis. 2014 May;34(2):123-33. doi: 10.1055/s-0034-1375954. Epub 2014 May 31. Review.

PMID:
24879978
40.

Human leukocyte antigen (HLA) pharmacogenomic tests: potential and pitfalls.

Daly AK.

Curr Drug Metab. 2014 Feb;15(2):196-201.

PMID:
24694233
41.

Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease.

Aravinthan A, Mells G, Allison M, Leathart J, Kotronen A, Yki-Jarvinen H, Daly AK, Day CP, Anstee QM, Alexander G.

Cell Cycle. 2014;13(9):1489-94. doi: 10.4161/cc.28471. Epub 2014 Mar 11.

42.

Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.

Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, Day CP, Daly AK, Reeves HL, Anstee QM.

J Hepatol. 2014 Jul;61(1):75-81. doi: 10.1016/j.jhep.2014.02.030. Epub 2014 Mar 6.

PMID:
24607626
43.

Is there a need to teach pharmacogenetics?

Daly AK.

Clin Pharmacol Ther. 2014 Mar;95(3):245-7. doi: 10.1038/clpt.2013.184.

PMID:
24548988
44.

Opportunities and limitations: the value of pharmacogenetics in clinical practice.

Daly AK, Cascorbi I.

Br J Clin Pharmacol. 2014 Apr;77(4):583-6. doi: 10.1111/bcp.12354. No abstract available.

45.

A randomized trial of genotype-guided dosing of warfarin.

Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group.

N Engl J Med. 2013 Dec 12;369(24):2294-303. doi: 10.1056/NEJMoa1311386. Epub 2013 Nov 19.

46.

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.

Verhoef TI, Redekop WK, Daly AK, van Schie RM, de Boer A, Maitland-van der Zee AH.

Br J Clin Pharmacol. 2014 Apr;77(4):626-41. doi: 10.1111/bcp.12220. Review.

47.

Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser.

Elsharkawy AM, Schwab U, McCarron B, Burt AD, Daly AK, Hudson M, Masson S.

J Clin Virol. 2013 Sep;58(1):331-3. doi: 10.1016/j.jcv.2013.05.003. Epub 2013 Jun 12.

PMID:
23763943
48.

Relevance of CYP2E1 to non-alcoholic fatty liver disease.

Daly AK.

Subcell Biochem. 2013;67:165-75. doi: 10.1007/978-94-007-5881-0_5. Review.

PMID:
23400921
49.

Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.

Daly AK.

Arch Toxicol. 2013 Mar;87(3):407-20. doi: 10.1007/s00204-013-1013-9. Epub 2013 Feb 2. Review.

PMID:
23376975
50.

Pharmacogenomics of adverse drug reactions.

Daly AK.

Genome Med. 2013 Jan 29;5(1):5. doi: 10.1186/gm409. eCollection 2013. Review.

Supplemental Content

Support Center